Unidrug Innovative Pharma Technologies Profile
Key Indicators
- Authorised Capital ₹ 20.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 9.58 Cr
as on 17-11-2024
- Company Age 37 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 27.99 Cr
as on 17-11-2024
- Satisfied Charges ₹ 16.87 Cr
as on 17-11-2024
- Revenue 0.38%
(FY 2023)
- Profit -23.85%
(FY 2023)
- Ebitda -17.28%
(FY 2023)
- Net Worth 13.70%
(FY 2023)
- Total Assets 14.32%
(FY 2023)
About Unidrug Innovative Pharma Technologies
The Corporate was formerly known as Uni Drug Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 20.00 Cr and a paid-up capital of Rs 9.58 Cr.
The company currently has active open charges totaling ₹27.99 Cr. The company has closed loans amounting to ₹16.87 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Unidrug Innovative Pharma Technologies Limited India is Mahesh Nabar as CFO. Varsha Jain, Gajanand Agrawal, Bharat Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U85120MP1987PLC003875
- Company No.
003875
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
13 Mar 1987
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Unidrug Innovative Pharma Technologies Limited offer?
Unidrug Innovative Pharma Technologies Limited offers a wide range of products and services, including Common Disease Medicines, Anti Smoking Drugs, Pharma Ingredients & Raw Materials, Anti Infective API, Aromatic Hydrocarbon Solvent, 4-Chloro Benzophenone.
Who are the key members and board of directors at Unidrug Innovative Pharma Technologies?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Nabar  | CFO | 01-Aug-2018 | Current |
| Jainesh Jain | Managing Director | 20-Aug-1995 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Varsha Jain | Director | 05-Oct-1995 | Current |
| Gajanand Agrawal | Director | 20-Sep-2018 | Current |
| Bharat Jain | Director | 20-Sep-2018 | Current |
Financial Performance of Unidrug Innovative Pharma Technologies.
Unidrug Innovative Pharma Technologies Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.38% increase. The company also saw a substantial fall in profitability, with a 23.85% decrease in profit. The company's net worth Soared by an impressive increase of 13.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unidrug Innovative Pharma Technologies?
In 2023, Unidrug Innovative Pharma Technologies had a promoter holding of 76.88% and a public holding of 23.12%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Oct 2024 | ₹1.50 M | Open |
Others Creation Date: 29 Jan 2024 | ₹2.50 M | Open |
Others Creation Date: 21 Nov 2023 | ₹1.50 M | Open |
How Many Employees Work at Unidrug Innovative Pharma Technologies?
Unidrug Innovative Pharma Technologies has a workforce of 33 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unidrug Innovative Pharma Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unidrug Innovative Pharma Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
